Skip to content
Search

Latest Stories

GPhC issues warning about online prescribing practice

The General Pharmaceutical Council (GPhC) has issued a warning relating to online prescribing services after identifying serious patient safety concerns.

It has reminded pharmacy owners and professionals to adhere the guidance for providing pharmacy services at a distance, including on the internet, whenever they provide online pharmacy services.


GPhC said, "Our inspectors are continuing to identify serious patient safety concerns relating to registered pharmacies dispensing of prescription-only medicines from prescribers based in the EEA working alone or for third-party online prescribing service using online questionnaire-only based models."

Its Director of Insight, Intelligence and Inspection, Claire Bryce-Smith, has written to organizations representing pharmacies and pharmacy professionals asking them to remind their members and networks of the importance of meeting the standards and following the guidance.

Claire’s letter highlights that since April 2019, enforcement action has been taken against over 40 pharmacies linked to their provision of online pharmacy services.

The majority of these pharmacies were working with online prescribing services that were prescribing medicines that are liable to abuse, misuse, and overuse to people, on the basis of an online questionnaire. The pharmacists involved have also been referred for Fitness to Practise investigations.

The Pharmacists' Defence Association (PDA) has welcomed an announcement from the regulator about “Patient safety concerns relating to online prescribing services.”

"As a pharmacist led organisation with extensive experience of situations where these issues have occurred, the PDA supports members to protect patients and reduce their exposure to personal risk," it said in a statement.

Mark Pitt, Director of Defence Services at the PDA, says: “The PDA is seeing a significant uplift in members seeking support and legal representation regarding regulatory investigations into online prescribing pharmacies. Our employment legal team are also representing pharmacist whistle-blowers who are concerned about poor patient care, through swift and effective intervention to protect their legal position.”

Members who are concerned about unsafe practices by their employer should contact the PDA service centre for advice at the earliest opportunity by emailing enquiries@the-pda.org.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less